|
|
|
|
|
Altretamine
drug data and news
Altretamine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Altretamine | ||
| Brand Names/Synonyms | Altretamine; Altretaminum [Inn-Latin]; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexamethylmelamine; Hexastat; Melamine, Hexamethyl-; NC 195 | ||
| Indication | For use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Altretamine is a novel antineoplastic agent. The precise mechanism by which altretamine exerts its cytotoxic effect is unknown, although a number of theoretical possibilities have been studied. Structurally, altretamine resembles the alkylating agent triethylenemelamine, yet in vitro tests for alkylating activity of altretamine and its metabolitics have been negative. Altretamine has been demonstrated to be efficacious for certain ovarian tumors resistant to classical alkylating agents. Metabolism of altretamine is a requirement of cytotoxicity. Synthetic monohydroxymethylmelamines, and products of altretamine metabolism, in vitro and in vivo, can form covalent adducts with tissue macromolecules including DNA, but the relevance of these reactions to antitumor activity is unknown. | ||
| Mechanism Of Action | The precise mechanism by which altretamine exerts its cytotoxic effect is unknown. | ||
| Altretamine News (When available) |
| ||
| Dosage Forms | CAPSULE | ||
| Drug_Category | Antineoplastic Agents; ATC:L01XX03 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Altretamine: Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamine's half-life and toxicity in a rat model. Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity; however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1 | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | N2,N2,N4,N4,N6,N6-hexamethyl-1,3,5-triazine-2,4,6-triamine | ||
| Chemical Formula | C9H18N6 | ||
| Molecular Weight | 210.28 g/mol | ||
| Smiles String | CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C | ||
| Melting Point | 172-174 °C | ||
| Water Solubility | 91 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 1.566 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 4.7-10.2 hours | ||
| Protein Binding [%] | 94% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Altretamine.html http://www.rxlist.com/cgi/generic/altretamine.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00652 | ||
| CAS Registry Number | 645-05-6 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:155900 | ||
| PharmGKB ID | PA448337 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2126230 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |